Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
At a glance
- Drug Originator Medarex; Ono Pharmaceutical
- Drug Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
- USA Patent Applicants BRISTOL MYERS SQUIBB
- USA Patents 388
- BLAs 2
- International Patents 4,798

Disclaimer